-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Tuesday's After-Market Session

Benzinga·07/29/2025 21:06:19
Listen to the news

Gainers

  • Salarius Pharmaceuticals (NASDAQ:SLRX) stock increased by 27.1% to $1.27 during Tuesday's after-market session. The company's market cap stands at $1.5 million.
  • Aclaris Therapeutics (NASDAQ:ACRS) shares increased by 16.77% to $1.81. The market value of their outstanding shares is at $181.9 million.
  • AtriCure (NASDAQ:ATRC) stock rose 10.36% to $35.02. The company's market cap stands at $1.6 billion. As per the news, the Q2 earnings report came out today.
  • Moleculin Biotech (NASDAQ:MBRX) shares increased by 10.26% to $0.79. The company's market cap stands at $16.6 million.
  • LakeShore Biopharma (NASDAQ:LSB) shares moved upwards by 9.93% to $0.99. The market value of their outstanding shares is at $38.4 million.
  • Leap Therapeutics (NASDAQ:LPTX) stock moved upwards by 8.44% to $0.36. The market value of their outstanding shares is at $14.0 million.

Losers

  • Cardiff Oncology (NASDAQ:CRDF) shares fell 28.7% to $2.36 during Tuesday's after-market session. The company's market cap stands at $248.1 million. The company's, Q2 earnings came out today.
  • Larimar Therapeutics (NASDAQ:LRMR) stock fell 11.34% to $3.13. The company's market cap stands at $233.0 million.
  • NeOnc Technologies (NASDAQ:NTHI) stock declined by 10.23% to $4.48. The company's market cap stands at $102.9 million.
  • 180 Life Sciences (NASDAQ:ATNF) shares declined by 9.94% to $2.9. The company's market cap stands at $17.5 million. As per the press release, Q2 earnings came out 4 days ago.
  • NewGenIvf Group (NASDAQ:NIVF) stock declined by 7.48% to $0.43. The market value of their outstanding shares is at $3.6 million.
  • Dyadic International (NASDAQ:DYAI) stock decreased by 6.09% to $1.08. The market value of their outstanding shares is at $33.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.